AlzeCure to present at the Pharma Outsourcing conference in Stockholm
AlzeCure Pharma AB (publ) (FN STO: ALZCUR), a pharmaceutical company that develops small molecule drugs for diseases affecting the nervous system, focusing on Alzheimer's disease and pain, today announced that the company’s co-founder and Head of Discovery & Research, Dr. Pontus Forsell, will present at the Pharma Outsourcing conference in Stockholm, Sweden, on December 3, 2024.
AlzeCure Pharma, a company that has progressed several first in class molecules in different areas of CNS and pain from discovery to clinic, is invited to present its collaboration and outsourcing strategy, from HTS to clinical phase phase 2 studies. The presentation will be held on December 3, at 2.10pm at Life City, the new event venue close to Karolinska Institutet in Stockholm.
“Our outsourcing strategy has been based on strengthening the projects in areas where we have lacked certain skills or opportunities to carry out the work ourselves. We have successfully worked with different service providers in the various drug development stages and we will showcase how we have worked with outsourcing from discovery phase into clinical development,” said Dr. Forsell.
Dr. Forsell has a PhD in Medical Biochemistry & Biophysics from Karolinska Institutet and more than 25 years of experience from several biotechnology and pharmaceutical companies, such as AstraZeneca, Biolipox, Orexo, and Merck in project and management positions. He is an expert in early drug development in the disease areas of neurology, pain and inflammation.
